Trelegy Ellipta Powder
NDC Package 0173-0887-14

The code 0173-0887-14 identifies a specific commercial package of 1 tray in 1 carton / 1 inhaler in 1 tray / 14 powder in 1 inhaler of Trelegy Ellipta, a human prescription drug labeled by Glaxosmithkline Llc. This powder is formulated for respiratory (inhalation) use and contains fluticasone furoate; umeclidinium bromide; vilanterol trifenatate as the active substance.

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaxosmithkline Llc on September 18, 2017. The current certification is valid through December 31, 2026.

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00173088714. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.